UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

Cancer chemotherapy and pharmacology, 2015-04, Vol.75 (4), p.791-803

2015

Volltextzugriff (PDF)

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

EBioMedicine, 2021-11, Vol.73, p.103651-103651, Article 103651

2021

Volltextzugriff (PDF)

PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors

Clinical pharmacology and therapeutics, 2024-07

2024

Volltextzugriff (PDF)

Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response

British journal of clinical pharmacology, 2015-01, Vol.79 (1), p.56-71

2015

Volltextzugriff (PDF)

Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study

Clinical pharmacology and therapeutics, 2023-08, Vol.114 (2), p.413-422

2023

Volltextzugriff (PDF)

A Minimal Continuous-Time Markov Pharmacometric Model

The AAPS journal, 2017-09, Vol.19 (5), p.1424-1435

2017

Volltextzugriff (PDF)

Simulation-based evaluation of the Pharmpy Automatic Model Development tool for population pharmacokinetic modeling in early clinical drug development

CPT: pharmacometrics and systems pharmacology, 2024-08

2024

Volltextzugriff (PDF)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer

Clinical pharmacology and therapeutics, 2023-01, Vol.113 (1), p.124-134

2023

Volltextzugriff (PDF)

A pharmacokinetic binding model for bevacizumab and VEGF(165) in colorectal cancer patients

Cancer chemotherapy and pharmacology, 2015-04, Vol.75 (4), p.791

2015

Volltextzugriff (PDF)

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Blood, 2022-11, Vol.140 (Supplement 1), p.10137-10139

2022

Volltextzugriff (PDF)

A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory

Pharmaceutical research, 2018-06, Vol.35 (6), p.122-14, Article 122

2018

Volltextzugriff (PDF)

Pharmacometric Analysis of the Relationship Between Absolute Lymphocyte Count and Expanded Disability Status Scale and Relapse Rate, Efficacy End Points, in Multiple Sclerosis Trials

Journal of clinical pharmacology, 2018-10, Vol.58 (10), p.1284-1294

2018

Volltextzugriff (PDF)

Abstract 843: Development of a quantitative systems pharmacology model for clinical dose and schedule optimization of RG6234, a T-cell engaging antibody targeting GPRC5D in multiple myeloma

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.843-843

2023

Volltextzugriff (PDF)

Pharmacometrics to improve clinical benefit assessment in oncology

Schindler, Emilie

2018

Volltextzugriff (PDF)

PK‐PD modeling of individual lesion FDG‐PET response to predict overall survival in patients with sunitinib‐treated gastrointestinal stromal tumor

CPT: pharmacometrics and systems pharmacology, 2016-04, Vol.5 (4), p.173-181

2016

Volltextzugriff (PDF)

A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients

CPT: pharmacometrics and systems pharmacology, 2017-06, Vol.6 (6), p.373-382

2017

Volltextzugriff (PDF)

998. Forward and Reverse Translational Approaches to Predict Efficacy of the Neutralizing Respiratory Syncytial Virus (RSV) Antibody MK-1654

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S590-S590

2021

Volltextzugriff (PDF)

Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib‐Treated Patients With Gastrointestinal Stromal Tumors

CPT: pharmacometrics and systems pharmacology, 2017-07, Vol.6 (7), p.449-457

2017

Volltextzugriff (PDF)

A pharmacokinetic binding model for bevacizumab and VEGF^sub 165^ in colorectal cancer patients

Cancer chemotherapy and pharmacology, 2015-04, Vol.75 (4), p.791

2015

Volltextzugriff (PDF)

Analyzing Patient-Reported Outcomes in Breast Cancer throughItem-Response Theory Pharmacometric Modeling

Journal of pharmacokinetics and pharmacodynamics, 2015, Vol.42 (Suppl. 1), p.S23

2015

Volltextzugriff (PDF)

From coast to coast to coast: ecology and management of seagrass ecosystems across Canada

Facets (Ottawa), 2021-02, Vol.6 (1), p.139-179

2021

Volltextzugriff (PDF)

Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis: The TOPAS-TAVI Registry

Journal of the American College of Cardiology, 2018-03, Vol.71 (12), p.1297-1308

2018

Volltextzugriff (PDF)

Immunofluorescence Technique to Detect Subcellular Structures Critical to Oocyte Maturation

Methods in molecular biology (Clifton, N.J.), 2018, Vol.1818, p.67

2018

Volltextzugriff (PDF)

Deeper waters are changing less consistently than surface waters in a global analysis of 102 lakes

Scientific reports, 2020, Vol.10 (1), p.20514-15, Article 20514

2020

Volltextzugriff (PDF)

The Role of Socioeconomic Status in the Association of Lung Function and Air Pollution-A Pooled Analysis of Three Adult ESCAPE Cohorts

International journal of environmental research and public health, 2019-05, Vol.16 (11), p.1901

2019

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(33)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(19)
Humans
(12)
Pharmacology & Pharmacy
(12)
Adult
(7)
Female
(7)
Life Sciences
(6)
Male
(6)
Models, Biological
(6)
Aged
(4)
Antineoplastic Agents - Therapeutic Use
(4)
Metastasis
(4)
Middle Aged
(4)
Original
(4)
Treatment Outcome
(4)
Aged, 80 And Over
(3)
Biomarkers
(3)
Cardiac & Cardiovascular Systems
(3)
Cardiovascular System & Cardiology
(3)
Clinical Trials
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors

Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response

Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study

A Minimal Continuous-Time Markov Pharmacometric Model

Simulation-based evaluation of the Pharmpy Automatic Model Development tool for population pharmacokinetic modeling in early clinical drug development

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer

A pharmacokinetic binding model for bevacizumab and VEGF(165) in colorectal cancer patients

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory

Pharmacometric Analysis of the Relationship Between Absolute Lymphocyte Count and Expanded Disability Status Scale and Relapse Rate, Efficacy End Points, in Multiple Sclerosis Trials

Abstract 843: Development of a quantitative systems pharmacology model for clinical dose and schedule optimization of RG6234, a T-cell engaging antibody targeting GPRC5D in multiple myeloma

Pharmacometrics to improve clinical benefit assessment in oncology

PK‐PD modeling of individual lesion FDG‐PET response to predict overall survival in patients with sunitinib‐treated gastrointestinal stromal tumor

A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients

998. Forward and Reverse Translational Approaches to Predict Efficacy of the Neutralizing Respiratory Syncytial Virus (RSV) Antibody MK-1654

Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib‐Treated Patients With Gastrointestinal Stromal Tumors

A pharmacokinetic binding model for bevacizumab and VEGF^sub 165^ in colorectal cancer patients

Analyzing Patient-Reported Outcomes in Breast Cancer throughItem-Response Theory Pharmacometric Modeling

From coast to coast to coast: ecology and management of seagrass ecosystems across Canada

Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis: The TOPAS-TAVI Registry

Immunofluorescence Technique to Detect Subcellular Structures Critical to Oocyte Maturation

Deeper waters are changing less consistently than surface waters in a global analysis of 102 lakes

The Role of Socioeconomic Status in the Association of Lung Function and Air Pollution-A Pooled Analysis of Three Adult ESCAPE Cohorts

Suchergebnisse filtern